Drugs / PERPHENAZINE 4-AMINOBUTYRATE
PERPHENAZINE 4-AMINOBUTYRATE
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00480246 | May 2007 → ? | — | BioLineRx, Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00567710 | Jul 2008 → Jul 2009 | schizophrenia | BioLineRx, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00722176 | Jun 2008 → Jul 2009 | schizophrenia | BioLineRx, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00480571 | Jun → Dec 2007 | schizoaffective disorder, schizophrenia | BioLineRx, Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01363349 | May 2011 → Mar 2013 | schizophrenia | BioLineRx, Ltd. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERPHENAZINE 4-AMINOBUTYRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187646 ↗ |
| Known as | BL-1020 | “BL-1020 is a γ-aminobutyric acid (GABA)-enhanced antipsychotic that combines dopamine antagonism with GABA agonist activity.” PMID 23059159 ↗ Sep 2012 |
| Known as | CYP-1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01363349 ↗ |
| Modality | Small molecule | — CHEMBL1187646 ↗ |
| Route | Oral | “single oral doses of BL-1020 or Perphenazine” NCT00480246 ↗ |